MGMT and lung carcinoma: Over 10-fold inter-individual variation in MGMT activity has been observed in normal tissues [6, 7], and lower MGMT activity is associated with therapy related leukemia [8], myelotoxicity in patients receiving temozolomide [9], and lung cancer risk [10].